Today was a good end to a strange trading week, while many shares had light volume with today's half-day trading session. Non-Farm payrolls declined worse than expected to 62,000, and May was revised higher to 62,000 jobs lost as well. The ISM non-Manufacturing came in again under 50 at a very weak 48.2, signaling growth isn't back to being close to the table. The dollar traders were probably less than thankful after the European Central Bank raised its overnight rates and as oil neared $146.00 per barrel intra-day. These are today's unofficial closing bell levels:
Abbott Labs (NYSE: ABT) saw a rise of almost 1% to $54.75 after the FDA approved its XIENCE drug eluting stent.
NVIDIA (NASDAQ: NVDA) saw a horrific drop after the company's earnings warnings. This is what happens when your new product fails enough that it increased the severity. Shares were down 30% at $12.49 at the close.
Penn National Gaming (NASDAQ: PENN) actually rose despite the merger finally being called off. We knew this was coming. Shares closed up 3.7% at $29.66 today.
Have a great weekend, and remember markets are closed Friday in observance of the July 4 holiday.
Abbott Laboratories (NYSE: ABT) got approval for its new drug-coated stent. The products are used to open clogged arteries, often in the place of by-pass surgery. The field has been dominated by deeply troubled medical device company Boston Scientific (NYSE: BSX). It looks that the weakened company is in for much more pain.
According toThe Wall Street Journal, ABT "received regulatory approval for its Xience V drug-coated stent, which is expected to be the top seller in the roughly $2 billion U.S. market because it appears to be more effective than rival devices." Boston Scientific will sell the new Abbott product, but with 40% of the revenue going to its rival, it is hard to see how that is a good deal.
BSX has been beaten by competition at almost every turn. It took on tremendous debt when it bought medical device company Guidant. It faced trouble when some Guidant products hit quality control issues. Boston Scientific stents came under criticism a year ago, when medical research questioned how effective they were.
BSX traded at almost $45 in 2004. It is now at about $12. With new competition and a bad balance sheet, that is not likely to change much.
Douglas A. McIntyre is an editor at 247wallst.com.
Many of us would be happy to benefit from a quiet retirement without facing concerns of losing all of our hard earned money. Fortune 40 gives us a helping hand by suggesting some big names to invest in that could offer us the results that we are looking for.
One such company is Abbott Laboratories (NYSE: ABT), whose earnings surged 35% during its last quarter, helped by its famous anti-inflammatory drug Humira and HIV treatment Kaletra. Looking ahead to the company's performance, CEO Miles White is planing to keep his main attention on its medical devices unit which is seen as a key element against strong competition.
Fortune 40 also looks at beverage maker The Coca-Cola Company (NYSE: KO), which benefits from strong international gains able to beat recent weakness in U.S. In addition, it looks like the company's acquisition of Glacéau and its VitaminWater brand offer it a good support to outperform on the market.
Retire Rich: Best Stocks to Retire On FORTUNE's trademark long-term portfolio can help put you on the road to a secure future. They include Abbott Labs, Coca-Cola, Procter & Gamble, Cisco, 3M, Walgreen, Cascade, Novaratis and Vodafone to name a few of the 40 stocks on FORTUNE's list. Fortune 40: Best stocks to retire on - FORTUNE Shoppers Beware: Products Shrink, But Prices Remain the Same There's a reason why the tub of ice cream you bought last week looks a tad smaller than ones you bought last summer. It is. Many major ice cream makers, hit by higher dairy costs, have shrunk their standard containers to 1.5 quarts from 1.75 quarts, about 1 cup less. As packaged goods makers' costs rise, they eventually have just two choices: raise prices or put less stuff in the package. While most are trying a price boost first, a growing number are shrinking the contents of their packages -- from Frito Lay's chips to Dial soap to Dreyer's ice cream. Other shrinking products include Hellmann's mayo down to 30 oz. from 32 oz., Cheerios & Wheaties have shrunk 1.5oz., Bounty papertowels down to 60 from 52 towels and more. Shoppers beware: Products shrink but prices stay the same - USATODAY.com
The average price of gas finally crossed $4 last week, perhaps on its way to $5.
According toThe Wall Street Journal, "The record nationwide average for regular-gasoline prices, announced by auto club AAA, follows Friday's near-$11 surge in oil prices to a record $138.54 a barrel."
While it makes a good headline, it is really no more important than when gas went above $3.95 or if and when it moves above $.4.05. What is important is that, at the current level, gas on its own could break the back of the consumer, and of many businesses.
It is not unusual for drivers to use 20 gallons of gas a week. For that consumer, the difference between $2 gas and $4 gas is $2,100 a year. A family making $40,000 is probably keeping $30,000 after taxes. So, 7% or 8% of their net income now goes to gasoline. That does not leave much for the rising cost of food and a mortgage.
The news is obviously just as bad for industries like farming and the airlines.
If investors want to see where the economy and markets are going, watch gas prices. They are probably a better proxy for how bad things are for the consumer than any other single measure. Gas at $5 would be a catastrophe.
Douglas A. McIntyre is an editor at 247wallst.com and author of the Ten Stocks Under $10 letter.
"You can invest for all the right reasons and still get the wrong result," notes long-standing turnaround stock expert George Putnam, referring to the poor performance of the pharmaceutical sector in recent years.
Here, in his industry-leading The Turnaround Letter, he offers a fascinating review of 10 leading drug stocks which he now believes offer a combination of growth potential at "pretty cheap" valuations. Here is his overview.
"In 2000 and 2001, when the Internet boom was becoming a bust, many smart investors turned away from technology stocks and put their money into drug stocks. How could you go wrong with the big pharmaceutical companies?
"Demand for their products was growing as the population aged. These companies had huge research and development programs that seemed to keep cranking out new blockbuster drugs. And most of them had great balance sheets, with many paying handsome dividends.
"Much of this reasoning has been borne out in the intervening years. Many large drug manufacturers have rung up substantial revenue gains over the last decade. So what's happened to the big drug stocks? With few exceptions they have gone sideways or down – in some cases down a lot.
MOST NOTEWORTHY: SunPower, Evergreen Solar and Abbott Lab were today's noteworthy initiations:
Citigroup believes SunPower (NASDAQ: SPWR) is faced with high cell production costs, its silicon cost and installation cost advantages are increasingly commoditized and finds the risk/reward even at current levels. Shares were initiated with a Hold rating and $105 target.
Citigroup believes Evergreen Solar (NASDAQ: ESLR) faces significant financing requirements over the next few years, making it difficult to see a sustained period of EPS growth beyond the $1 range. The firm sees downside to $5/share. Shares were assumed with a Sell rating and $8 target.
UBS started Abbott Lab (NYSE: ABT) with a Buy rating and $61 target. The firm is positive on Humira potential growth and expects Xience to drive vascular operating margins to positive.
It's a fairly quiet day in analyst land as far as the most active stocks are concerned, despite there being many movers today. Here is a brief snapshot of some of the key calls today:
Abbott Labs (NYSE: ABT) started as Buy at UBS. DRS Tech (NYSE: DRS) cut to Neutral at UBS; cut to market perform at FBR.
FreightCar America (NASDAQ: RAIL) Raised to Buy from Hold at Jefferies; new price target $42.00 from $35.00.
Among the many variables business executives, policy makers, and economists are watching as the United States attempts to jump-start its slow growth / no growth economy, is the ability of oil's price to moderate in the quarters ahead.
Further, oil's failure, to date, to fall below $110 per barrel despite three straight months of declining U.S. gasoline consumption and sluggish economic growth has caused oil watchers to re-examine their premises regarding projected oil prices for 2008-2012.
The oil market, circa May 2008
Over the past decade, the world has encountered both a tripling of oil prices and the start of the $100 per barrel oil era, driven largely by increasing demand for oil in emerging markets, particularly in the giga-GDP growth nations of China and India. Further, one 'dampening assumption' during oil's recent climb to record heights has been that the price of oil would fall as the U.S. economy approached a recession, and as global growth slowed.
Abbott Laboratories (NYSE: ABT) shares are trading higher after the Food and Drug Administration denied regulatory approval for Merck & Co.'s (NYSE: MRK) cholesterol drug Cordaptive. The Merck drug would have directly competed with ABT's own cholesterol drug. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on ABT.
After hitting a one-year low of $49.58 in July, the stock hit a one-year high of $61.09 in January. ABT opened this morning at $53.32. So far today the stock has hit a low of $52.97 and a high of $53.73. As of 12:10, ABT is trading at $53.24, up $1.63 (3.2%). The chart for ABT looks bearish and steady, while S&P gives the stock a positive 4 STARS (out of 5) buy rating.
For a bullish hedged play on this stock, I would consider a June bull-put credit spread below the $50 range. A bull-put credit spread is an options position that combines the purchase and sale of put options to hedge risk in case the stock doesn't do what you think but still leverage nice returns. For this particular trade, we will make a 13.6% return in just seven weeks as long as ABT is above $50 at June expiration. Abbott would have to fall by more than 6% before we would start to lose money. Learn more about this type of trade here.
The euro climbed to a record-high $1.6020 versus the dollar Tuesday, after the European Central Bank signaled that they'll increase interest rates -- despite slowing growth -- if inflation accelerates, Bloomberg News reported.
The euro rose about 1.5 cents to $1.6020 versus the dollar before paring some gains to trade around $1.5985 in Tuesday afternoon trading. The Euro also rose about four-tenths of a pence against the British pound to 80.20 pence.
Dollar falls, again
Meanwhile, the dollar retreated across the board, falling about 1.5 cents to $1.9950 versus the British pound and about one-half yen to 102.95 versus Japan's yen. Independent currency trader Andrew Resnick told BloggingStocks Tuesday that traders responded to the ECB's announcement by doing what you'd expect: they bought the euro.
"The only thing holding back the euro was the possibility the ECB would cut rates. The fundamentals have been in the euro's favor for several years. The market had priced-in a possible rate cut by the ECB, but when ECB comments came in today the market quickly bid up the euro," Resnick said. He added that he is presently long with the euro against the dollar.
Shares of drug company Abbott Laboratories Inc. (NYSE: ABT) were trading higher this morning after the company reported that its first-quarter profit jumped 35%, helped by strong international demand for its rheumatoid arthritis medication Humira. However, the stock is down 1% just before noon.
For the quarter, Abbott Laboratories reported that its profit climbed to $938 million, or 60 cents per share, boosted by higher sales of its prescription drugs and medical devices that benefited from favorable foreign exchange rates. Excluding special items, the company's earnings came in at 63 cents a share, beating analysts' estimations for quarterly earnings of 62 cents a share.
The pharmaceutical company also announced a 14% growth in revenues, to $6.77 billion, up from $5.95 billion a year earlier. Revenue during the period was helped by a 54% increase in its drug Humira sales which surged to $878 million in the first quarter. Analysts, on average, were expecting the company show $6.53 billion in revenue, according to Thomson Financial.
After hitting a one-year low of $49.58 in July, the stock hit a one-year high of $61.09 in January. ABT opened this morning at $53.81. So far today the stock has hit a low of $53.62 and a high of $55.40. As of 1:00, ABT is trading at $55.07, up $2.00 (3.8%). The chart for ABT looks bearish and steady, while S&P gives the stock a positive 4 STARS (out of 5) buy rating.
For a bullish hedged play on this stock, I would consider a May bull-put credit spread below the $47.50 range. A bull-put credit spread is an options position that combines the purchase and sale of put options to hedge risk in case the stock doesn't do what you think but still leverage nice returns. For this particular trade, we will make a 4.2% return in just 7 weeks as long as ABT is above $47.50 at May expiration. Abbott would have to fall by more than 13% before we would start to lose money. Learn more about this type of trade here.
ABT hasn't been below $49 at all in the past year and has shown support around $51 recently. This trade could be risky if the company's earnings (due out in mid to late May) disappoint, but even if that happens, this position could be protected by the support the stock might find around $50, where it has bottomed out quite a few times in the past two year. Brent Archer is an options analyst and writer at Investors Observer.
DISCLOSURE: Mr. Archer owns and/or controls diversified portfolios of long and short stock and option positions that may include holdings in companies he writes about. At publication time, Brent neither owns nor controls positions in ABT or BSX.
MOST NOTEWORTHY: Abbott Lab, Fannie Mae, Freddie Mac and Micromet were today's noteworthy upgrades:
Wachovia upgraded Abbott Lab (NYSE: ABT) to Outperform from Market Perform as they believe their earlier concerns have been addressed. Past concerns included the potential for a negative outcome from the FDA panel on Xience and slowing prescription growth of lead drug Humira.
Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE) were raised to Outperform from Market Perform at Keefe Bruyette citing recent government actions to stabilize the mortgage markets.
Micromet (NASDAQ: MITI) was upgraded at RBC Capital to Outperform from Sector Perform as they expect positive data for its lead candidate, MT103, by year-end.
OTHER UPGRADES:
ThinkEquity raised Atheros Comm (NASDAQ: ATHR) to Buy from Accumulate.
Goldman upgraded US Steel (NYSE: X) to Buy from Neutral.
General Electric (NYSE: GE) was upgraded at Merrill to Buy from Neutral.
Many of us would be happy to benefit from a quiet retirement without facing concerns of losing all of our hard earned money. Fortune 40 gives us a helping hand by 
The average price of gas finally crossed $4 last week, perhaps on its way to $5. 
.gif){kind=logo}
y variables business executives, policy makers, and economists are watching as the United States attempts to jump-start its slow growth / no growth economy, is the ability of oil's price to moderate in the quarters ahead.
Here are some highlights from this past week's .gif){kind=logo}
Comfort Zone Investing: Keep your recovery expectations real
Will Americans have to slim down to fit into their cars?
Starbucks: The next McDonald's
